GL1X · GenesisL1 explorer

MolNFT v1 · #54427 · protein

C-terminal cysteine-rich domain of human chfr bound to madpr

2XOC · E3 ubiquitin-protein ligase chfr: “C-terminal cysteine-rich domain of human chfr bound to madpr”. X-ray diffraction, 3 ligands (ADE, ADP, ZN), 3 pockets (best druggability 0.58). MolNFT v1 #54427 on GenesisL1: 3D structure, binding…

PDB
2XOC
Type
protein
Length
425 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
E3 ubiquitin-protein ligase chfr
EC
6.3.2.-
UniProt
Q96EP1
Ligands
ADE, ADP, ZN
Pockets
3 · best druggability 0.58

Structure

x-ray diffraction · 2 distinct chains · 37% helix, 8% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AE3 ubiquitin-protein ligase chfr (EC 6.3.2.-)protein21336% helix, 8% strandQ96EP1
BE3 ubiquitin-protein ligase chfr (EC 6.3.2.-)protein21238% helix, 8% strandQ96EP1

Ligands and binding sites

  • ADE · Adenine · ligand · 2 copies · chains B
  • ADP · Adenosine-5'-diphosphate · ligand · chains A, B
  • ZN · Zinc ion · metal · 10 copies · chains A, B
  • PGE · Triethylene glycol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11820.580.8126ADP
2570.280.7416empty
3570.270.7414empty

Interfaces

1 interface between chains.

  • A–B · 473 Ų buried · 5 hydrogen bonds · protein-protein

Compared structures

  • 2XOC · C-terminal cysteine-rich domain of human CHFR bound to mADPr · the same entry in another collection · chain A against A, TM-score 1.00
  • Q96EP1 · AlphaFold monomer V2.0 prediction for E3 ubiquitin-protein ligase chfr (Q96EP1) · a predicted model of the same protein · chain B against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.